Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

ACTIVE NOT RECRUITING

NCT04002180

Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Crohn's Disease]

Sponsor: Takeda

View on ClinicalTrials.gov

Summary

The purpose of this survey is to evaluate the long-term safety and effectiveness of vedolizumab for intravenous (IV) infusion 300 milligrams (mg) in Crohn's disease (CD) patients in the routine clinical setting.

Official title: Specified Drug-Use Survey on Entyvio for IV Infusion 300 mg [Crohn's Disease]

Key Details

Gender

All

Age Range

Any - Any

Study Type

OBSERVATIONAL

Enrollment

335

Start Date

2019-07-01

Completion Date

2026-06-30

Last Updated

2026-01-07

Healthy Volunteers

Conditions

Crohn's Disease

Interventions

DRUG

Vedolizumab (Genetical Recombination)

Vedolizumab IV infusion

Locations (1)

Takeda Selected Site

Tokyo, Japan